- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Vor Biopharma Stock Soars 73% On $175 Mln Private Placement Deal | 3 | RTTNews | ||
| Do | Vor Bio Reinvents Itself as an Autoimmune Biotech With In-Licensed Phase 3 Asset and $175M in Funding | 1 | MedCity News | ||
| Do | Vor Bio's surprise $4B revival deal for RemeGen's autoimmune drug triggers divergent stock reactions | 2 | FiercePharma | ||
| VOR BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| Do | Vor Bio surges after private placement, licensing deal | 2 | Seeking Alpha | ||
| Do | Vor Biopharma stock soars after licensing deal for autoimmune therapy | 2 | Investing.com | ||
| Do | Stifel maintains hold rating on Vor Biopharma stock amid strategic shift | 1 | Investing.com | ||
| Do | Vor Bio revives, thanks to $4bn+ licensing deal with RemeGen | 3 | pharmaphorum | ||
| Do | Pre-market Movers: Vor Biopharma, Worthington Steel, Surf Air Mobility, Nano Labs, Protagenic Therapeutics | 258 | AFX News | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 07.30 A.M. ET).In the Green Vor Biopharma Inc. (VOR) is up over 109% at $1.16.
Worthington... ► Artikel lesen | |
| Do | Why Vor Bio Is Rising In Pre-market? | 5 | RTTNews | ||
| Do | China's RemeGen Inks USD4.1 Billion Autoimmune Disorders Drug Deal With US' Vor Bio | 11 | Yicai Global | ||
| Do | Vor Bio secures global rights to RemeGen autoimmune drug with $175M funding | 3 | Investing.com | ||
| Do | Vor Bio sichert sich globale Rechte an RemeGen-Autoimmunmedikament mit 175 Mio. US-Dollar Finanzierung | 12 | Investing.com Deutsch | ||
| Do | REMEGEN Grants Vor Bio Exclusive Development Rights for Telitacicept Outside Greater China | 1 | AASTOCKS | ||
| Do | Vor Biopharma Inc. - 8-K, Current Report | - | SEC Filings | ||
| Mi | Vor Bio secures $175 million in private placement financing | 2 | Investing.com | ||
| Mi | Vor Bio announces $175M private placement | 1 | Seeking Alpha | ||
| Mi | Vor Bio sichert sich 175 Millionen US-Dollar durch Privatplatzierung | 10 | Investing.com Deutsch | ||
| Mi | Vor Bio acquires rights to telitacicept for autoimmune diseases | 1 | Investing.com | ||
| Mi | Vor Bio erwirbt Rechte an Telitacicept für Autoimmunerkrankungen | 4 | Investing.com Deutsch | ||
| Mi | Vor Biopharma: Vor Bio Announces $175 Million Private Placement | 140 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it has entered... ► Artikel lesen |
1 2 3 Weiter >>
53 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TARSUS PHARMACEUTICALS | 40,330 | 0,00 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports First Quarter 2025 Financial Results and Recent Business Achievements | Generated $78.3 million in net product sales of XDEMVY®, an increase of 217% year over year and 18% over Q4 2024, and dispensed approximately 72,000 bottles to patients Strengthened financial position... ► Artikel lesen | |
| SPRINGWORKS THERAPEUTICS | 46,990 | 0,00 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Receives Positive CHMP Opinion for Nirogacestat for the Treatment of Adults with Desmoid Tumors | - If approved, nirogacestat will be the first and only therapy with marketing authorization in the EU for the treatment of desmoid tumors -
- Decision from European Commission expected in the third... ► Artikel lesen | |
| QIAGEN | 41,040 | -0,46 % | Minimale Kursveränderung bei Qiagen NV-Aktie (40,55 €) | Am Aktienmarkt ist der Anteilsschein von Qiagen NV gegenwärtig unauffällig. Das Wertpapier kostete zuletzt 40,55 Euro. Der heutige Börsentag brachte bislang wenig Kursbewegung bei der Aktie von Qiagen... ► Artikel lesen | |
| VERVE THERAPEUTICS | 11,255 | 0,00 % | BMO Capital stuft Verve Therapeutics nach Eli Lilly-Übernahme herab | ||
| RECURSION PHARMACEUTICALS | 5,410 | 0,00 % | Recursion Pharmaceuticals: Recursion Reports First Quarter 2025 Financial Results and Provides Business Update | Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing... ► Artikel lesen | |
| ADMA BIOLOGICS | 18,380 | 0,00 % | Will Strong Asceniv Sales Drive ADMA Biologics Further? | ||
| KYMERA THERAPEUTICS | 45,720 | 0,00 % | Gilead Sciences Partners Kymera Therapeutics To Develop Novel Oral Molecular Glue CDK2 Degraders | FOSTER CITY (dpa-AFX) - Gilead Sciences, Inc. (GILD) and Kymera Therapeutics, Inc. (KYMR) announced Wednesday that they have entered into an exclusive option and license agreement to accelerate... ► Artikel lesen | |
| BIONTECH | 91,00 | +0,39 % | Die nächste Cashcow? Schnelle Prozente mit NetraMark, Moderna, BioNTech | Erinnern Sie sich noch an den Impfstoff-Wettlauf in der Corona-Zeit? Damals bestimmte das Duell zwischen BioNTech und Curevac auch das Geschehen an der Börse. Anleger der ersten Stunde machten schnell... ► Artikel lesen | |
| EVOTEC | 7,150 | -0,64 % | Evotec-Aktie: Kurs legt zu (6,734 €) | Am deutschen Aktienmarkt notiert die Evotec-Aktie derzeit etwas fester. Zuletzt zahlten Investoren für das Wertpapier 6,73 Euro. Der Anteilsschein von Evotec verzeichnet gegenwärtig einen Preisanstieg... ► Artikel lesen | |
| ITEOS THERAPEUTICS | 10,020 | 0,00 % | iTeos Therapeutics Inc.: iTeos Therapeutics Announces Its Intention to Wind Down Operations | - Board of Directors intends to cease operations - Company to focus efforts on selecting best path to deliver near-term value to shareholders - Exploring potential asset sales including EOS-984, EOS-215... ► Artikel lesen | |
| PHATHOM PHARMACEUTICALS | 9,550 | 0,00 % | Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | FLORHAM PARK, N.J., June 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal... ► Artikel lesen | |
| KEROS THERAPEUTICS | 13,510 | 0,00 % | Keros Therapeutics, Inc.: Keros Announces Return of $375 Million in Excess Capital to Stockholders | LEXINGTON, Mass., June 09, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 13,050 | 0,00 % | Edgewise Therapeutics Reports Positive Results on Sevasemten Program for Becker and Duchenne Muscular Dystrophies | - New open label data in Becker demonstrated sustained disease stabilization up to three years, reinforcing prior clinical findings -- Ongoing pivotal trial and FDA Type C meeting provide... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 21,310 | 0,00 % | H.C. Wainwright Sticks With Bullish Call on Summit Therapeutics, $44 Target | ||
| IMMUNOME | 8,790 | 0,00 % | Immunome Inc. - 8-K, Current Report |
VOR BIOPHARMA INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,890 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VOR BIOPHARMA INC finden Sie auf Wallstreet Online.